NCT04387084View on ClinicalTrials.gov

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

August 12, 2026

Study Completion Date

August 12, 2027

Conditions
Advanced Malignant Skin NeoplasmMetastatic Malignant Skin Neoplasm
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Avelumab

Given IV

BIOLOGICAL

Cemiplimab

Given IV

BIOLOGICAL

Durvalumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Short-Term Fasting

Undergo STF

BIOLOGICAL

Dostarlimab

Given IV

BIOLOGICAL

Retifanlimab

Given IV

BIOLOGICAL

Toripalimab

Given IV

BIOLOGICAL

Tislelizumab

Given IV

Trial Locations (2)

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER